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Abstract 
 
 
The development of platelet concentrates has generated great expectations in bone 
surgery. These compounds provides autologous growth factors for tissue healing 
and regeneration, but disparity of methods hinders the patterns of use. The 
objective of our study is proposing a standard model for Platelet Rich Plasma 
preparation, involving growth factors release. Sheep peripheral blood were obtained 
with anticoagulant citrate dextrose 50 N (Citra), three different speed centrifugation 
methods and plasma activation (1000 units of thrombin and 10% CaCl2 per ml were 
performed. The release of growth factors were determined by ELISA (R & D 
systems).  The higher platelets concentration was obtained with two centrifugations, 
first 500 g 10 min, followed by 1900g for 8 min. After activation clotting immediate 
release of growth factors by platelet degranulation were achieved. The PDGF 
increased more than 1.9 fold till 537.9 pg/ml and TGF-β1 increases almost 8 times 
till 7150 pgr/ml in 180 min. Our standard method proposed, triggers the release of 
growth factors, immediately after activation with a dose-response relationship 
between platelets and growth factors. This means that the PRP prepared in our 
experimental conditions is really a plasma rich in growth factors ready for clinical 
use. 
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1.  Background 
 
The development of platelet concentrates has generated great expectations in 
bone surgery. 
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These surgical use concentrates, given different names depending on the 
composition both in cell series and growth factors. The P-PRP, platelet-rich plasma 
pure, also called PRGF or PRF, the L-PRP leukocytes platelet rich plasma, P-PRF, 
plasma fibrin-rich and L-PRF rich plasma both in fibrin and lecucocitos. (Dohan 
Ehrenfest D.M.,et al 2012 &,Schär MO., Diaz-Romero J., Kohl S., Zumstein MA., 
Nesic D. 2015) 
 
These compounds are designed to deliver growth factors and provides an easy 
and low cost high concentration of autologous growth factors for the tissue healing 
and regeneration (Cho, Kim, Kwon, Kim, Choi& Kim2014; Shen, Gao, Zhang & He 
2015). But how the PRP is prepared? How the activation and as the release of growth 
factors is produced? Today it remains misunderstand and no consensus achieved. 
Several methods of obtaining platelet concentrates has been published and has 
determined the amount of growth factors, but such is the number of different 
methods, which actually  we are not talking about the same compound, and therefore 
it is not possible to compare to one another. The autologous PRP is the combination 
of seven natural growth factors within a normal clot who acts as carrier. (Lane, 
Tomin, & Bostrom 1999; Gil Albarova, Garrido Lahiguera, Gil Albarova & Melgosa 
Gil 2003; Sanchez et al. 2009). 
 
These growth factors such as TGF-β, PDGF, VEGF etc. are tissue 
promotors, and healing by acting on cell chemotaxis, proliferation and differentiation, 
tissue debris removal, angiogenesis and matrix extracelular fixation (Torrella, Toledo, 
Hondares &, Calañas 2003). Even act as  cell signal transducers  and as a cellular 
communications network (Landesberg, Roy & Glickman2000; Eppley, Woodell & 
Higgins J. 2004; Sánchez Martin2005).Different platelet concentrates have been used 
in both animal and human models in the treatment of musculoskeletal injuries 
(Soomekh2011 & Hapa O. et al. 2012), dental implants evaluation (De Obarrio, 
Arausz-Dutari & Chamberlain 2000; Preeti & Anisha2013), as a biological glue 
(Findikcioglu, Findikcioglu, Yavuzer, Elmas & Atabay 2009; Dong et al. 2012; Dragoo 
2012; Lee 2012) with completely contradictory results., It has beneficial clinical effect 
in patients with tendopathies but otherwise the role of PRP in orthopedic surgery 
remains unknown (Bonete 2007; Bonete, Carrasco&Gomar 2010). 
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In the use of PRP  the more growth factors  released and located in the 
wound, more stem cells are stimulated to produce new tissue, therefore, it allow 
probably  the body  heal faster and more efficiently (Zechner et al. 2003; Kawasumi, 
Kitoh, Siwicka & Ishiguro 2008). But there are still many questions to be answered 
about PRP preparation, risks and clinical use. At present there is no consensus on the 
use, production and characterization of PRP and to a pattern establishment we need 
more clinical studies (Carrasco, Bonete & Gomar 2009; Malhotra, Pelletier, Yu & 
Walsh 2013). 
 
Landesberg21 demonstrated that platelet activation is affected by various 
factors such as the release of growth factors, the type of coagulant used, the rate and 
duration of the centrifugation, and gel preparation (Landesberg, Roy & 
Glickman2000; Eppley, Woodell & Higgins 2004; Gandhi, Bibbo, Pinzur & Lin 2005; 
Everts, Knape & Weibrich et al.2006). Some researchers have relied on manual 
protocols developed for concentrating platelets in humans (Ohba et al.2012), which 
use the double centrifugation to increase the number and time of centrifugation speed 
(Carrasco,  Bonete & Gomar 2011; López, Giraldo & Carmona 2012, Bausset O. et al 
2014). The leukocytes presence, type and amount in the PRP concentrate has been 
controversial (Carmona, López & Giraldo 2011; Giovanini et al.2012) it can benefit 
the tissue regeneration processes but leukocytes are involved in the formation of 
fibrosis and increased inflammation (Chizzolini, Brembilla, Montanari & 
Truchetet2011). The choice of platelet activator can significantly influence the release 
kinetics. Collagen activation shows a sustained release pattern for 30 days, while the 
pattern of release of growth factors following activation by thrombin without 
leukocytes remains unknown.  
 
The studies and results disparity provides very little clinical evidence with 
great variability in the preparation of concentrates and in the number of platelets and 
growth factors which hinders the patterns of use (Carrasco, Bonete & Gomar 2009; 
Preeti & Anisha 2013). 
 
The main objective of our study is to propose a model using standardized 
application of P-PRP, we have carried out an experimental study involving the growth 
factors PDGF and TGF-β1 identification and quantification. its correlation with the 
number of platelets and release kinetics after activation with thrombin providing the 
general use conditions.  
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2. Materials and Methods 
 
2.1 Blood Sample Preparation 
 
Blood samples were obtained from peripheral blood 10 merino sheep 
extracted into 4 ml tubes with 0.32 ml of ADC A (anticoagulant citrate dextrose 
solution 50 N Citra clot MA), at pH 7.46 (physiological conditions) The tubes were 
stirred and kept on ice The blood thus obtained was separated into two sample 
groups, one with whole blood as a control and the other to obtain PRP in different 
concentration methods and platelet separation. 
 
2.2 Platelet Counting 
 
The counting was performed by automated cell counter Abbot, model 
Celldyn-3700. Platelet rich plasma was prepared from peripheral blood collected with 
citrate dextrose, the tubes were centrifuged at 500, 600 and 750 g for 10 minutes, 
whereby the platelet phase were separated and leukocytes and erythrocytes were 
discarded. Then a second centrifugation at 1900 g was carried out for 8 minutes to 
concentrate the platelets. Samples were used for counting platelets and activated by 
the addition of 1000 units of thrombin (Sigma Co., St. Louis Mo.) and 10% CaCl2 per 
ml for clot formation (Figure 1). Samples without addition were used as control. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Clot Formation 
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2.3 Growth Factor Quantification 
 
Each sample clotted was used to determine levels of PDGF and TGF β1 by 
ELISA (R & D system, Minneapolis Minn.) according to the manufacturer's 
instructions. At least 5 determinations were carried out for each sample. 
 
2.4 PDGF and TGF-β1 Basal Levels  
 
To determine the basal values of PDGF and TGF-β1 by ELISA, plasma was 
extracted from peripheral blood kept on ice with EDTA as anticoagulant. The 
samples were centrifuged at 1000 g for 30 minutes and then a second centrifugation at 
10,000 g was performed for 10 minutes at 2-8 ° C in an Eppendorf 5415 Centrifuge. 
 
2.5 Growth Factors P-PRP Levels 
 
P-PRP growth factors from peripheral blood with anticoagulant ACD A, were 
determined after activation with 1000 units of thrombin and 10% CaCl2 per ml. Once 
the gel has formed, it takes less than 5 minutes, we proceeded to growth factors 
collection by centrifugation at 1500 g for 5 min, and supernatant sample aliquots were 
taken at 10 ', 60' and 180 ' and were frozen at -80 ° C. (). Determination of TGF-β1 
activation in ELISA required acid medium (1N HCl) and incubation for 24 hours at 
2-8 ° C. The linear regression of the calibration curves for both growth factors were 
calculated. Correlation coefficient spractically equivalent to unit. Table I 
 
Table I: Linear Regresion. ELISA Growth Factor Determination 
PDGF Abs 504-570nm=0.0011* pgr PDGF -0.0182  R =0.999 
TGF β1 Abs 450-570nm=0.0007*pgr TGF Β1 – 0.0563 R = 0.9929 
 
2.6 Statistical Analysis 
 
All values are expressed as mean ± std with vc (variation coefficient) and 
comparison between groups was performed using the Student t test. In cases where a 
comparison involving more than two groups the analysis of variance (ANOVA) was 
used to assess significant differences between groups. If significant differences were 
confirmed each difference was examined using the Pearson coefficient. Correlation 
studies were made between the concentration of platelets in the gel and the release of 
growth factors. The probability was considered statistically significant if P <.05 
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3. Results 
 
3.1 Counting Blood Cells  
 
The platelet count were obtained for peripheral blood (basal value428750 
±41719, 3) Table II. The platelet-rich plasma for each sample method, one 
centrifugation (500g, 123000, 600 g81000, 750 g36500) and after a second 
centrifugation of 1900g (500 g, 167,5 ·106 , 600 g 149, 5·106, 750 g  142·106) (Tables  
III and IV).  
 
 
We have determined the platelets number in three different PRP methods of 
preparation. The results show that only one centrifugation method, the number of 
platelets is smaller, due to a significant drag effect or cell washing. On the other hand 
the number of platelets is enhanced when the samples have been centrifuged twice 
(Table IV). reaching an increase of three orders of magnitude (103) under these 
conditions. 
 
 
Table II.  Average Value of the Number of Platelets in Peripheral Blood 
Platelets/ml 
Samples of blood   N=5 
mean 428750 
std 41719,3 
v.c. 0,0947 
Table III: Average Value of the Number of Platelets Determinated in PRP 
by one Centrifugation. Platelets/ml 
Centrifuged 
10 min 
A. 500 g B. 600 g C. 750 g 
mean 123000 81000 36500 
std 12727.9 2828.42 4949.74 
v.c. 0.1034 0.0349 0,135 
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Table  IV: Value of the Number of Platelets Determinated in PRP by a 2nd 
Centrifugation  1900 g. Platelets/ml 
 A. 500 g B.600 g C.750 g 
Mean 167,5 ·106 149,5·106 142·106 
std 30,4,106 24,7,106 19,79,106 
v. c. 0,181 0,165 0,139 
 
3.2 Growth Factors Determination 
 
We have observed that growth factors baseline values for PDGF is 281.31 
pgr/ml and for TGF β1 is 785.48 pgr/ml (Table V). with a variation coefficient less 
than 15 %. (4.5 and 12.3 respectively) 
 
Table V: Basal Level of growth Factors in Peripheral Blood 
 mean std v. c. 
PDGF pgr/ml 281.31 12.79 0.045 
TGF β1 pgr/ml 785.48 96.94 0.123 
 
The effect of the activation with thrombin and calcium chloride after clotting 
is the immediate release of growth factors by platelet degranulation in all centrifuging 
methods. After activation the PDGF increased more than 1.5 fold the maximum 
obtained was 1.9 fold 537.9pg/ml (Table VI). 
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In the case of TGF-β1 increases more than 4 fold, even, in the case of 500 g is 
almost 8 times till 7150 pgr/ml.  That means a huge increase of growth factors 
release (Table VII). 
 
Table VII: TGF  β1  Released 
A.500 g  mean  std v.c.  Pgr/ml Released %  
10 min  4697  900  0.19  6365 65.69  
60 min  4944  49  0.009  8 times 69.14  
180 min  7150  762  0.100  100.0  
B.600 g       
10 min  3724  200.0  0.053  3754 82.04  
60 min  3935  65.5  0.016  4.7 times 86.69  
180 min  4539  150  0.033  100.0  
C.750 g       
10 min  4324  198.0  0.045  3886 92.57  
60 min  4772  250.0  0.052  4.9 times 102.1  
180 min  4671  368  0.078  100.0  
Table VI: PDGF Released 
A.500 g  mean  std v.c..  pgr/ml released  %  
10 min  505.0  27.0  0.0549  256.0 93.88  
60 min  518.4  27.0  0.053  96.37  
180 min  537.9  4.3  0.008  1.9 times 100.0  
B.600 g       
10 min  470.7  2.01  0.0042  189.39 100.0  
60 min  454.06  19.7  0.043  96.46  
180 min  427.82  21.69  0.0506  1.5  times 91.02  
C.750 g       
10 min  449.77  30.5  0.0678  209.58 91.62  
60 min  489.88  22.7  0.0463  99.79  
180 min  490.89  11.09  0.0226  1.7 times 100.0  
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3.3 Kinetics of Growth Factors release  
 
The release of the growth factors was monitored for 250 minutes. PDGF was 
released by 93.88% in the first 10 ', while TGF β1 was released only 65% in the first 
10'. (Figure II). The release of TGF β1 is slower, peaking after 3 hours. Not 
significantly increasing from this time (data not shown). 
 
 
 
Figure 2: PDGF and TGF β1 Kinetic Release 
 
The release rate for groth factors peaks in the first 10 min, reaching maximum 
for TGF β1 almost 450 pg/min and for PDGF, 50 pg/min, these values are not 
sustained in time. 
 
 
 
Figure 3: Growth Factor Release Rate. Máximum Releases at 10 Minutes, not 
Sustained in Time 
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The ratio between   TGF β1 /PDGF increases constantly in the first 180 min 
with a polynomial  regression of . r20.947. TGF  β1  is released   11 times more. Fig 4 
 
 
 
Figure 4: Estechiometry TGF β1 /PDGF (pgr). (1º centrifugation 500 g/2º 190 
g) 
 
3.4 Statistical Correlation 
 
Growth factors release are related to platelets number, while PDGF release is 
linked to the release of TGF-β1-dependent manner (Pearson coeff. R= 0.93, 0.96 in 
each case). The linear relationship between platelets number versus growth factors 
liberated is close to unity (r2 = 0.913) (Pearson coef. R = 0.92) (Table VIII). 
 
TABLA VIII: Pearson Correlation. * Closed to Unity 
 X(platelets) Y1(PDGF) Y2(TGFb1) 
 Rx,y1 Rx,y2 Ry1,y2 
Pearson coeficient *0.9244 *0.933 *0.9605 
Significance  
T student test 
P<0.05 
0.26 0.2535 0.1959 
Significance  
T student test 
P<0.01 
0.33 0.3145 0.2431 
Linear regression  R2=0.855 R2=0.847 
y = -0.077x2 + 1.935x + 1.332
R² = 0.947
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4. Discussion 
 
The use of platelet rich plasma (PRP) or plasma rich in growth factors PRF 
has been a breakthrough in the stimulation and acceleration of the consolidation of 
bone and soft tissue. This technology has the risk that is not understood exactly so 
handling and misuse (Bonete Lluch, 2007) is performed, given the great variability of 
methods of preparation and use different application conditions (Carrasco, Bonete & 
Gomar 2009; Malhotra, Pelletier, Yu & Walsh 2013)The application of proteins 
released by platelets is particularly important in pathological states such as fracture 
healing compromised as a result of inadequate biological environment with very low 
concentrations of TGF, IGF and PDGF (Roldan et al. 2004).Based on the different 
methods of PRF preparation, our first objective was to quantify the platelets basal 
level  in the peripheral blood (Table I). Also the platelets was quantified in terms of 
the method of centrifugation. For one single centrifugation Anitua’s method 
(Anituaet al. 2004) concentration is low because a lot of platelets carried by the red 
and white cell layers is lost (Table II). Therefore, it is necessary to centrifuge the 
sample twice, then platelets concentrate much more. In our study three different 
centrifugation speeds in response to the literature was performed. Thus the three 
methods used the higher concentration of platelets was obtained with  two 
centrifugations  first 500 g for 10 ' discarding supernatant and followed by 1900g for 
8' (Table III). 
 
We have analyzed the values of TGF β1 and PDGF, as they are considered 
two of the most important growth factors and they are found in highest concentration 
in platelets. Thus, TGF β1 is in the fracture hematoma within 24 hours after injury 
and is the major growth factor involved in the regulation of bone and cartilage 
formation after injury and in new bone growth remodeling (Laurencin 2003; Cho et al 
2014). Moreover PDGF synthesis increases in response to external stimuli such as low 
oxygen tension and or thrombin stimulation of other growth factors. PDGF is 
secreted by platelets in the fracture callus factor which can stimulate recruitment of 
reparative cells and other mesenchymal cell types (Yuniko Abe, Asanura, Tonomura, 
Kimura &, Masuda2007; Schär, Diaz-Romero, Kohl, Zumstein & Nesic 2015). In our 
research group, in a previous experimental study in rabbits in which a cortical defect 
was created in the tibia and fibula, no significant correlation was found between 
platelet count and geometric and densitometric variables analyzed following the use of 
PRP or PRF (BoneteLluch, 2007). PRP use does not alter the repair and healing 
processes in the control group (Bonete, Carrasco & Gomar 2010).  
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The levels of TGF β1 and PDGF in our samples obtained agree with the 
experimental work of Eppley et al ( Eppley, Woodell & Higgins 2004) to yield a 
positive relationship in the number of growth factors released and the number of 
platelets in contrast to reports by other authors (Weibrich, Kleis, Hafner & Hitzler 
2002; Mazzucco, Balbo, Cattana, Guaschino, Borzini 2009). (Table VIII) 
 
Platelet activation by calcium chloride gel is based on the participation of 
calcium in platelet activation (Gruber, Varga, Fisher & Watzek2002; Yuniko Abe, 
Asanura, Tonomura, Kimura& Masuda 2007). By contrast, in vitro, it was found that 
the addition of CaCl2 did not activate platelets, consequently no degranulation was 
produced and therefore no growth factors were released (Bielecki & Dohan Ehrenfest 
2012). For this reason the use of CaCl2 is necessary but with other activators. For this 
study we used bovinethrombin.  
 
In our study the use of exogenous thrombin provides a quick release in the 
first 10 'reaching more than 90% of total release. Figure 2. These results are similar to 
those published by Harrison et al 2011, where thrombin activation generates the 
immediate release of growth factors and thrombin active exogenous TGF β1 from the 
latent form to the active form. The release of TGF β1 is much more slow and 
cumulative over time (Figure 2, Table VI and VII) as occurs in collagen activation 
where the release of TGF β1 is also slower than that for PDGF. However, as shown 
in Figure 3 the discharge of TGF β1 speed release (> 450 pgr / min) is much greater 
than that generated in the PDGF (50 pgr / min) due to the activation mechanism of 
thrombin by reaction platelet enzymatic cleavage. Thrombin excess can lead to 
irreversible platelet degranulation with the loss of integrity of the platelets and 
subsequent release of growth factors (Ranly, Lohmann, Andreacchio, Boyan & 
Schwartz 2007). 
 
The estechiometry between TGF β1/PDGF in basal levels is almost 2.8, after 
activationit increases till 11 fold. The requeriments of TGF β1 in the cell seems to be 
higher with a polinomialincrease tripling initial values in the first 3 hours after 
activation. r2 0.947 in the  polinomial regression.(Fig 4), The TGF group of cytokines 
is necessary for initiate signaling via receptors for the post injury histogenesis 
(Villapol,  Logan, &Symes 2013).The relation between TGF β1 and PDGF release is 
maintained for at least 3 hours to afford a greater release of TGF β1 from around 11 
times. 
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The release of specific growth factors in our samples agrees  those ofFufa 
group (Fufa, Shealy, Jacobson, Kevy & Murray 2008) that observed release growth 
factors at significant levels in both the collagen- like activation with thrombin 
(Harrison et al 2011). These studies seem to suggest that the PRP can have beneficial 
effects on the proliferation of bone marrow stem cells (Wen et al 2014) without 
promoting osteoblast differentiation. It should be noted that this factor release occurs 
in the absence of erythrocytes and leukocytes so we can rule out any possible 
interference that may distort the composition of our PRP in clinical use. The main 
limitation of our study is precisely the determination of only two growth factors, the 
most commonly used in published papers, but do not know what the answer of other 
cytokines . So VEGF levels could be altered by not sampled levels of lymphocytes 
and neutrophils as in many platelet concentrates. 
 
The lack of consensus on the composition and production of plasma 
concentrates makes it impossible to establish a rule covering all published research. 
 
5. Conclusions 
 
1. Activation of platelets with thrombin and CaCl2 exogenous triggers the release of 
growth factors, immediately after activation. In the case of PDGF especially in the 
first 10 minutes in the case of TGF β1 release is slower and this continued up to 3 
hours after application. This means that the PRP prepared in our experimental 
conditions is really a plasma rich in growth factors ready for clinical use. 
2. Appears to be a dose-response relationship between the number of platelets and 
growth factors released as well as between growth factors together (statistically 
significant).  
3. The best method of obtaining PRP for use in studies of bone healing in the 
presence of growth factors would be by two centrifugations, the first of 500 g for 
10 'and the second of 1900 g for 8'. Under these conditions an average of 537.9 pgr 
PDGF / ml and 7.150 pgr TGF β1/ml are released in situ and are maintained for 
at least 3 hours. 
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